Which Are The Toughest Diseases Area To Achieve Clinical Success In?
In the last decade, on average, only one in 10 Phase I drug development programs conducted in the US have successfully advanced all the way to FDA approval. Meanwhile, despite more than a third of industry's R&D budget being spent on Phase III trials, 42% of programs fail to progress from there, according to a new report from BIO and Informa's Pharma Intelligence.
You may also be interested in...
In Vivo's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in May 2021. Data provided by Biomedtracker.
Deal-making and financing activities are on the rise for liquid biopsy diagnostic products in 2021 despite questions remaining around whether the technology can unseat standard-of-care biomarker and imaging tests.
Kate Broderick, SVP of research and development at INOVIO and one of In Vivo’s 2021 rising leaders, is hopeful that greater collaboration will be the lasting effect of COVID-19.